S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   446.15 (-2.08%)
MSFT   212.26 (-1.89%)
FB   270.11 (+1.82%)
GOOGL   1,499.27 (-0.38%)
AMZN   3,174.98 (-1.55%)
NVDA   447.18 (-1.38%)
CGC   16.81 (-4.05%)
BABA   248.82 (-6.35%)
TSLA   1,441.03 (-3.26%)
MU   48.33 (-0.76%)
GE   6.40 (+1.11%)
AMD   83.79 (-3.37%)
T   29.94 (+0.34%)
F   6.86 (-1.01%)
ACB   10.13 (-1.75%)
GILD   69.14 (+0.48%)
NFLX   491.26 (-3.50%)
DIS   130.45 (-0.28%)
BAC   26.08 (+2.39%)
BA   170.09 (-1.23%)
S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   446.15 (-2.08%)
MSFT   212.26 (-1.89%)
FB   270.11 (+1.82%)
GOOGL   1,499.27 (-0.38%)
AMZN   3,174.98 (-1.55%)
NVDA   447.18 (-1.38%)
CGC   16.81 (-4.05%)
BABA   248.82 (-6.35%)
TSLA   1,441.03 (-3.26%)
MU   48.33 (-0.76%)
GE   6.40 (+1.11%)
AMD   83.79 (-3.37%)
T   29.94 (+0.34%)
F   6.86 (-1.01%)
ACB   10.13 (-1.75%)
GILD   69.14 (+0.48%)
NFLX   491.26 (-3.50%)
DIS   130.45 (-0.28%)
BAC   26.08 (+2.39%)
BA   170.09 (-1.23%)
S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   446.15 (-2.08%)
MSFT   212.26 (-1.89%)
FB   270.11 (+1.82%)
GOOGL   1,499.27 (-0.38%)
AMZN   3,174.98 (-1.55%)
NVDA   447.18 (-1.38%)
CGC   16.81 (-4.05%)
BABA   248.82 (-6.35%)
TSLA   1,441.03 (-3.26%)
MU   48.33 (-0.76%)
GE   6.40 (+1.11%)
AMD   83.79 (-3.37%)
T   29.94 (+0.34%)
F   6.86 (-1.01%)
ACB   10.13 (-1.75%)
GILD   69.14 (+0.48%)
NFLX   491.26 (-3.50%)
DIS   130.45 (-0.28%)
BAC   26.08 (+2.39%)
BA   170.09 (-1.23%)
S&P 500   3,337.95 (-0.33%)
DOW   27,327.81 (-0.22%)
QQQ   270.65 (-1.45%)
AAPL   446.15 (-2.08%)
MSFT   212.26 (-1.89%)
FB   270.11 (+1.82%)
GOOGL   1,499.27 (-0.38%)
AMZN   3,174.98 (-1.55%)
NVDA   447.18 (-1.38%)
CGC   16.81 (-4.05%)
BABA   248.82 (-6.35%)
TSLA   1,441.03 (-3.26%)
MU   48.33 (-0.76%)
GE   6.40 (+1.11%)
AMD   83.79 (-3.37%)
T   29.94 (+0.34%)
F   6.86 (-1.01%)
ACB   10.13 (-1.75%)
GILD   69.14 (+0.48%)
NFLX   491.26 (-3.50%)
DIS   130.45 (-0.28%)
BAC   26.08 (+2.39%)
BA   170.09 (-1.23%)
Log in

NASDAQ:CDXSCodexis Stock Price, Forecast & News

$13.72
+0.87 (+6.77 %)
(As of 08/7/2020 01:51 PM ET)
Add
Compare
Today's Range
$12.99
Now: $13.72
$14.57
50-Day Range
$10.39
MA: $11.66
$12.87
52-Week Range
$8.43
Now: $13.72
$18.87
Volume24,766 shs
Average Volume333,708 shs
Market Capitalization$809.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.63
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Read More
Codexis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.46 million
Book Value$1.80 per share

Profitability

Net Income$-11,940,000.00

Miscellaneous

Employees132
Market Cap$809.75 million
Next Earnings DateN/A
OptionableOptionable
$13.72
+0.87 (+6.77 %)
(As of 08/7/2020 01:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Codexis (NASDAQ:CDXS) Frequently Asked Questions

How has Codexis' stock been impacted by COVID-19 (Coronavirus)?

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDXS shares have increased by 35.6% and is now trading at $13.72.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Codexis?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.02. The biotechnology company had revenue of $14.67 million for the quarter, compared to the consensus estimate of $12.53 million. Codexis had a negative net margin of 21.40% and a negative return on equity of 14.24%.
View Codexis' earnings history
.

What price target have analysts set for CDXS?

3 brokers have issued 1 year target prices for Codexis' shares. Their forecasts range from $16.00 to $21.00. On average, they expect Codexis' share price to reach $18.50 in the next year. This suggests a possible upside of 34.8% from the stock's current price.
View analysts' price targets for Codexis
.

Has Codexis been receiving favorable news coverage?

Media coverage about CDXS stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Codexis earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Codexis
.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 55)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
  • Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & Marketing
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 73)

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.36%), Assenagon Asset Management S.A. (1.00%), Ziegler Capital Management LLC (0.77%), Essex Investment Management Co. LLC (0.52%), Taylor Frigon Capital Management LLC (0.38%) and Swiss National Bank (0.21%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis
.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., New York State Common Retirement Fund, Ingalls & Snyder LLC, Essex Investment Management Co. LLC, Ziegler Capital Management LLC, UBS Group AG, and Envestnet Asset Management Inc.. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch.
View insider buying and selling activity for Codexis
.

Which major investors are buying Codexis stock?

CDXS stock was acquired by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Conestoga Capital Advisors LLC, Assenagon Asset Management S.A., First Trust Advisors LP, Swiss National Bank, Exchange Traded Concepts LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $13.72.

How big of a company is Codexis?

Codexis has a market capitalization of $809.75 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.